Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1 1

Status

Completed 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 4606Pancreatic Neoplasms 2845Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Colonic Neoplasms 1791Rectal Neoplasms 1720Esophageal Neoplasms 1376Liver Neoplasms 921Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 765Carcinoma, Non-Small-Cell Lung 707Cholangiocarcinoma 587Lung Neoplasms 557Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 514Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 264Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Esophagogastric Cancer × Gastrointestinal × Clear all
NCT03133650 2026-04-16

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
12 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT05796102 2026-03-05

PET-MRI

University Health Network, Toronto

Phase NA Recruiting
15 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Massachusetts General Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡